SCHEMBL8348342

SCHEMBL8348342

CN[C@@H](CO)C(=O)OCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
TACR1 P25103 1/20 0.48
MAPK1 P28482 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
SLC6A2 P23975 1/20 0.47
SLC6A3 Q01959 1/20 0.47
KMT2A Q03164 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
POLB P06746 1/20 0.46
S1PR1 P21453 2/20 0.45
MAPT P10636 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
CTSK P43235 3/20 0.45
THRB P10828 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
HSD17B10 Q99714 1/20 0.44
ACE P12821 1/20 0.44
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8351818 1.00 ALDH1A1 (0.53) ALDH1A1TACR1MAPK1L3MBTL1SLC6A2
Hydrochloric Acid SCHEMBL30844650 0.98 ALDH1A1 (0.51) ALDH1A1TACR1MAPK1L3MBTL1SLC6A2
SCHEMBL20804457 0.89 PPARA (0.53) ALDH1A1TACR1MAPK1L3MBTL1SLC6A2
SCHEMBL21444696 0.87 ALDH1A1 (0.53) ALDH1A1TACR1MAPK1L3MBTL1SLC6A2
SCHEMBL2059140 0.87 TACR1 (0.58) ALDH1A1TACR1POLBS1PR1MAPT
SCHEMBL13108402 0.87 TACR1 (0.58) ALDH1A1TACR1POLBS1PR1MAPT
SCHEMBL23011779 0.85 ALDH1A1 (0.51) ALDH1A1TACR1MAPK1L3MBTL1SLC6A2
SCHEMBL7400240 0.85 ALDH1A1 (0.51) ALDH1A1TACR1MAPK1L3MBTL1SLC6A2
SCHEMBL4954521 0.85 CTRB1 (0.52) ALDH1A1TACR1MAPK1L3MBTL1SLC6A2
SCHEMBL5019111 0.85 ALDH1A1 (0.51) ALDH1A1TACR1MAPK1L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250263365-A1 O-SUBSTITUTED SERINE DERIVATIVE PRODUCTION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-08-21 US disclosed
EP-3878836-B1 O-SUBSTITUTED SERINE DERIVATIVE PRODUCTION METHOD CHUGAI PHARMACEUTICAL CO LTD (JP) 2025-07-23 EP disclosed
US-12312297-B2 O-substituted serine derivative production method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-05-27 US disclosed
CN-112969683-B Process for the preparation of O-substituted serine derivatives 中外制药株式会社 2024-05-14 CN disclosed
US-20220017456-A1 O-SUBSTITUTED SERINE DERIVATIVE PRODUCTION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-01-20 US disclosed
US-20120289471-A1 NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX SIGNATURE R&D HOLDINGS, LLC (US) 2012-11-15 US disclosed
US-8188311-B2 L-threonine derivatives of high therapeutic index SIGNATURE R&D HOLDINGS, LLC (US) 2012-05-29 US disclosed
US-8173840-B2 Compounds with high therapeutic index SIGNATURE R&D HOLDINGS, LLC (US) 2012-05-08 US disclosed
US-20100069446-A1 L-THREONINE DERIVATIVES OF HIGH THERAPEUTIC INDEX SIGNATURE R&D HOLDINGS (US) 2010-03-18 US disclosed
US-20100069489-A1 L-THREONINE DERIVATIVES OF HIGH THERAPEUTIC INDEX SIGNATURE R&D HOLDINGS (US) 2010-03-18 US disclosed
US-7589233-B2 L-Threonine derivatives of high therapeutic index SIGNATURE R&D HOLDINGS, LLC (US) 2009-09-15 US disclosed
US-5948693-A COVALENTLY BONDING SIDE CHAIN OF SELECTED AMINO ACID TO SOLID SUPPORT VIA ACID-LABILE OR PHOTO-LABILE LINKER, PROTECTING C-TERMINUS, SYNTHESIZING POLYPEPTIDE ON N-TERMINUS, DEPROTECTING C-TERMINUS AND CYCLIZING POLYPEPTIDE WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1999-09-07 US disclosed
WO-1998046247-A1 SOLID PHASE SYNTHESIS OF IMMUNOSUPPRESSIVE AGENTS WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1998-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250263365-A1 O-SUBSTITUTED SERINE DERIVATIVE PRODUCTION METHOD STS, SMOX, TST ALDH1A1 616/4885TACR1 2831/4885MAPK1 1834/4885
US-20100069446-A1 L-THREONINE DERIVATIVES OF HIGH THERAPEUTIC INDEX BCAT1, AADAT, TPI1 ALDH1A1 1176/4885TACR1 1234/4885MAPK1 2904/4885
US-12312297-B2 O-substituted serine derivative production method STS, SMOX, TST ALDH1A1 616/4885TACR1 2831/4885MAPK1 1834/4885
US-20220017456-A1 O-SUBSTITUTED SERINE DERIVATIVE PRODUCTION METHOD STS, SMOX, TST ALDH1A1 616/4885TACR1 2831/4885MAPK1 1834/4885
US-20120289471-A1 NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX IL4I1, SLC7A1, GOT1 ALDH1A1 945/4885TACR1 1277/4885MAPK1 4669/4885
US-20100069489-A1 L-THREONINE DERIVATIVES OF HIGH THERAPEUTIC INDEX BCAT1, AADAT, TPI1 ALDH1A1 1176/4885TACR1 1234/4885MAPK1 2904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.